-
Ustekinumab, sold
under the
brand name
Stelara among others, is a
monoclonal antibody medication used for the
treatment of Crohn's disease, ulcerative...
-
treatment with
ustekinumab. It
showed that
patients who
switched to
guselkumab from
ustekinumab did
better than
those who
remained on
ustekinumab. "Tremfya...
-
program comprising four
clinical trials which compared risankizumab to
ustekinumab,
adalimumab and
placebo in the
indication of
plaque psoriasis. The results...
-
bimekizumab is
superior to not only
adalimumab but also
secukinumab and
ustekinumab for the
treatment of
plaque psoriasis. The
approval for the treatment...
-
development for
psoriasis has been
discontinued in the U.S. and Europe. Like
ustekinumab, the
antibody targets the
interleukins 12 and 23. The
candidate drug...
- tocilizumab-bavi/Tofidence tocilizumab/Actemra
October 2023
ustekinumab-auub/Wezlana
ustekinumab/Stelara
December 2023 bevacizumab-tnjn/Avzivi bevacizumab/Avastin...
-
share a
common domain, p40,
which is the
target of the FDA-approved
ustekinumab. In 2017 the US FDA
approved guselkumab for
plaque psoriasis.
There have...
-
showing superior skin
clearance in a
Phase III
trial when
compared to
ustekinumab and a placebo. However, in May 2015,
Amgen announced that it was ending...
- such as
vedolizumab and
natalizumab and
interleukin antagonists like
ustekinumab.
Prior to the
development of
biological therapy as a
modality to treat...
- needed]
Ustekinumab (CNTO 1275) is a
monoclonal antibody that
suppresses cytokines IL-12 and IL-23.
Originally designed to
treat psoriasis,
ustekinumab was...
